Nasdaq · CIK 0001674930
FLGT Fulgent Genetics, Inc.
Insider trading from SEC Form 4. Last filing 40 d ago. Close $21.74 on Oct 9, 2026, +58% from the 52-week low and -30% from the high.
Fulgent Genetics, Inc. (FLGT) has 106 SEC Form 4 filings on file from 7 insiders, the latest filed on Sep 3, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 2 open-market sells worth $75k, net -$75k.
29 open-market trades have been scored at FLGT. The newest: Hanlin Gao (Chief Scientific Officer) sold $33k of stock on Sep 2, 2026, filed Sep 3, 2026, scored 29 (weak). The largest of the 29 shown: Paul Kim (CFO and Treasurer) bought $1.6M on Mar 5, 2025, scored 53 (moderate). 2 insiders sold within 14 days of each other around Sep 2, 2026.
FLGT closed at $21.74 on Oct 9, 2026, 58% above its 52-week low and 30% below its 52-week high.
18 Form 144 notices of planned sales are on file, the latest filed Dec 1, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Fulgent Genetics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 29Weak | Hanlin Gao Chief Scientific Officer sell | $33k 1,673 shares | -0% | - | |
| 34Weak | Jian Xie President and COO sell | $42k 2,127 shares | -1% | - | |
| 28Weak | Hanlin Gao Chief Scientific Officer sell | $30k 1,688 shares | -0% | +36% from low-39% from high | |
| 34Weak | Jian Xie President and COO sell | $38k 2,146 shares | -1% | +36% from low-39% from high | |
| 23Weak | Hanlin Gao Chief Scientific Officer sell | $17k 945 shares | -0% | +30% from low-42% from high | |
| 28Weak | Jian Xie President and COO sell | $21k 1,201 shares | -0% | +30% from low-42% from high | |
| 28Weak | Hanlin Gao Chief Scientific Officer sell | $30k 1,075 shares | -0% | +86% from low-8% from high | |
| 33Weak | Jian Xie President and COO sell | $32k 1,140 shares | -0% | +86% from low-8% from high | |
| 28Weak | Hanlin Gao Chief Scientific Officer sell | $28k 943 shares | -0% | +94% from low-4% from high | |
| 34Weak | Jian Xie President and COO sell | $35k 1,198 shares | -0% | +94% from low-4% from high | |
| 23Weak | Hanlin Gao Chief Scientific Officer sell | $16k 535 shares | -0% | +101% from low0% from high | |
| 28Weak | Jian Xie President and COO sell | $21k 681 shares | -0% | +101% from low0% from high | |
| 42Moderate | Jian Xie President and COO sell | $291k 10,000 shares | -3% | +90% from low-2% from high | |
| 23Weak | Hanlin Gao Chief Scientific Officer sell | $23k 1,063 shares | -0% | +44% from low-4% from high | |
| 28Weak | Jian Xie President and COO sell | $25k 1,128 shares | -0% | +44% from low-4% from high | |
| 23Weak | Hanlin Gao Chief Scientific Officer sell | $20k 943 shares | -0% | +42% from low-6% from high | |
| 33Weak | Jian Xie President and COO sell | $26k 1,199 shares | -0% | +42% from low-6% from high | |
| 23Weak | Hanlin Gao Chief Scientific Officer sell | $12k 548 shares | -0% | +41% from low-6% from high | |
| 28Weak | Jian Xie President and COO sell | $15k 696 shares | -0% | +41% from low-6% from high | |
| 28Weak | Jian Xie President and COO sell | $23k 1,135 shares | -0% | +35% from low-10% from high | |
| 23Weak | Hanlin Gao Chief Scientific Officer sell | $15k 754 shares | -0% | +35% from low-10% from high | |
| 23Weak | Hanlin Gao Chief Scientific Officer sell | $21k 1,039 shares | -0% | +32% from low-12% from high | |
| 34Weak | Jian Xie President and COO sell | $38k 1,873 shares | -1% | +32% from low-12% from high | |
| 53Moderate | Paul Kim CFO and Treasurer buy | $1.6M 100,000 shares | +40% | - | |
| 35Weak | Hanlin Gao Chief Scientific Officer sell | $27k 1,373 shares | -0% | - | |
| 40Moderate | Jian Xie President and COO sell | $28k 1,455 shares | -0% | - | |
| 35Weak | Jian Xie President and COO sell | $13k 689 shares | -0% | - | |
| 46Moderate | Ming Hsieh Chief Executive Officer sell | $41k 2,227 shares | -0% | - | |
| 30Weak | Hanlin Gao Chief Scientific Officer sell | $9,075 497 shares | -0% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 1, 2025 | Xie Jian Officer | 1,135 0.00% of outstanding | $32k | Dec 2, 2025 | $372k |
| Dec 1, 2025 | Gao Hanlin Officer | 1,070 0.00% of outstanding | $31k | Dec 2, 2025 | $68k |
| Nov 26, 2025 | Gao Hanlin Officer | 943 0.00% of outstanding | $28k | Nov 28, 2025 | $72k |
| Nov 26, 2025 | Xie Jian Officer | 1,198 0.00% of outstanding | $36k | Nov 28, 2025 | $377k |
| Nov 24, 2025 | Gao Hanlin Officer | 535 0.00% of outstanding | $16k | Nov 24, 2025 | $55k |
| Nov 24, 2025 | Xie Jian Officer | 681 0.00% of outstanding | $21k | Nov 24, 2025 | $357k |
| Nov 19, 2025 | Xie Jian Officer | 10,000 0.03% of outstanding | $291k | Nov 19, 2025 | $66k |
| Sep 3, 2025 | Gao Hanlin Officer | 1,063 0.00% of outstanding | $23k | Sep 3, 2025 | $32k |
| Sep 3, 2025 | Xie Jian Officer | 1,128 0.00% of outstanding | $25k | Sep 3, 2025 | $41k |
| Aug 27, 2025 | Gao Hanlin Officer | 943 0.00% of outstanding | $20k | Aug 27, 2025 | $48k |
| Aug 27, 2025 | Xie Jian Officer | 1,199 0.00% of outstanding | $26k | Aug 27, 2025 | $76k |
| Aug 25, 2025 | Xie Jian Officer | 696 0.00% of outstanding | $15k | Aug 25, 2025 | $61k |
| Jun 2, 2025 | Xie Jian Officer | 1,135 0.00% of outstanding | $23k | Jun 2, 2025 | $38k |
| Dec 2, 2024 | Xie Jian Officer | 1,483 0.00% of outstanding | $29k | Dec 2, 2024 | $48k |
| Dec 2, 2024 | Gao Hanlin Officer | 1,397 0.00% of outstanding | $27k | Dec 2, 2024 | $42k |
| Nov 25, 2024 | Hsieh Ming Owner, Officer, Director | 2,227 0.01% of outstanding | $41k | Nov 25, 2024 | $53k |
| Nov 25, 2024 | Gao Hanlin Officer | 497 0.00% of outstanding | $9,075 | Nov 25, 2024 | $46k |
| Nov 25, 2024 | Xie Jian Officer | 689 0.00% of outstanding | $13k | Nov 25, 2024 | $51k |
Transactions
The newest 50 of 176 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Jian Xie President and COO | SOpen-market sale Common Stock | -2,127 | $19.66 | $42k | 359,924 | 40 d ago |
| Sep 1, 2026 | Ming Hsieh Chief Executive Officer | FTax withholding Common Stock | -4,392 | $19.59 | $86k | 885,952 | 40 d ago |
| Sep 1, 2026 | Paul Kim CFO and Treasurer | FTax withholding Common Stock | -2,087 | $19.59 | $41k | 356,543 | 40 d ago |
| Sep 2, 2026 | Hanlin Gao Chief Scientific Officer | SOpen-market sale Common Stock | -1,673 | $19.66 | $33k | 986,117 | 40 d ago |
| Jun 1, 2026 | Ming Hsieh Chief Executive Officer | FTax withholding Common Stock | -4,392 | $18.09 | $79k | 893,293 | Jun 3, 2026 |
| Jun 2, 2026 | Jian Xie President and COO | SOpen-market sale Common Stock | -2,146 | $17.89 | $38k | 367,605 | Jun 3, 2026 |
| Jun 2, 2026 | Hanlin Gao Chief Scientific Officer | SOpen-market sale Common Stock | -1,688 | $17.89 | $30k | 990,374 | Jun 3, 2026 |
| Jun 1, 2026 | Paul Kim CFO and Treasurer | FTax withholding Common Stock | -2,087 | $18.09 | $38k | 362,545 | Jun 3, 2026 |
| May 26, 2026 | Paul Kim CFO and Treasurer | FTax withholding Common Stock | -1,168 | $17.67 | $21k | 364,632 | May 28, 2026 |
| May 27, 2026 | Jian Xie President and COO | SOpen-market sale Common Stock | -1,201 | $17.60 | $21k | 369,751 | May 28, 2026 |
| May 27, 2026 | Hanlin Gao Chief Scientific Officer | SOpen-market sale Common Stock | -945 | $17.60 | $17k | 992,062 | May 28, 2026 |
| May 26, 2026 | Ming Hsieh Chief Executive Officer | FTax withholding Common Stock | -2,949 | $17.67 | $52k | 897,685 | May 27, 2026 |
| May 14, 2026 | Regina E Groves director | AGrant or award Common Stock | +11,117 | $0.00 | $0 | 28,099 | May 18, 2026 |
| May 14, 2026 | Michael Nohaile director | AGrant or award Common Stock | +5,558 | $0.00 | $0 | 24,578 | May 18, 2026 |
| May 14, 2026 | Linda Dong director | AGrant or award Common Stock | +11,117 | $0.00 | $0 | 38,758 | May 18, 2026 |
| May 14, 2026 | Michael Nohaile director | AGrant or award Stock Option (Right to Buy)derivative | +8,426 | $0.00 | $0 | 8,426 | May 18, 2026 |
| Apr 26, 2026 | Paul Kim CFO and Treasurer | FTax withholding Common Stock | -2,747 | $16.31 | $45k | 365,800 | Apr 28, 2026 |
| Apr 26, 2026 | Jian Xie President and COO | FTax withholding Common Stock | -4,361 | $16.31 | $71k | 370,952 | Apr 28, 2026 |
| Apr 26, 2026 | Hanlin Gao Chief Scientific Officer | FTax withholding Common Stock | -1,645 | $16.31 | $27k | 993,007 | Apr 28, 2026 |
| Mar 9, 2026 | Ming Hsieh Chief Executive Officer | JOther Forward sale contract (obligation to sell)derivativeindirect: By Trust | -750,000 | - | - | 0 | Mar 31, 2026 |
| Mar 9, 2026 | Ming Hsieh Chief Executive Officer | JOther Forward sale contract (obligation to sell)derivativeindirect: By Trust | -750,000 | - | - | 0 | Mar 11, 2026 |
| Feb 26, 2026 | Jian Xie President and COO | FTax withholding Common Stock | -1,140 | $24.76 | $28k | 384,539 | Mar 2, 2026 |
| Feb 26, 2026 | Paul Kim CFO and Treasurer | FTax withholding Common Stock | -1,168 | $24.76 | $29k | 378,027 | Mar 2, 2026 |
| Feb 26, 2026 | Ming Hsieh Chief Executive Officer | FTax withholding Common Stock | -2,949 | $24.76 | $73k | 918,200 | Mar 2, 2026 |
| Feb 26, 2026 | Hanlin Gao Chief Scientific Officer | FTax withholding Common Stock | -897 | $24.76 | $22k | 1,002,080 | Mar 2, 2026 |
| Mar 1, 2026 | Hanlin Gao Chief Scientific Officer | FTax withholding Common Stock | -1,018 | $15.33 | $16k | 1,001,062 | Mar 2, 2026 |
| Mar 1, 2026 | Paul Kim CFO and Treasurer | FTax withholding Common Stock | -1,133 | $15.33 | $17k | 376,894 | Mar 2, 2026 |
| Mar 1, 2026 | Ming Hsieh Chief Executive Officer | FTax withholding Common Stock | -17,566 | $15.33 | $269k | 900,634 | Mar 2, 2026 |
| Mar 1, 2026 | Jian Xie President and COO | FTax withholding Common Stock | -1,079 | $15.33 | $17k | 383,460 | Mar 2, 2026 |
| Mar 1, 2026 | Paul Kim CFO and Treasurer | FTax withholding Common Stock | -8,347 | $15.33 | $128k | 368,547 | Mar 2, 2026 |
| Mar 1, 2026 | Hanlin Gao Chief Scientific Officer | FTax withholding Common Stock | -6,410 | $15.33 | $98k | 994,652 | Mar 2, 2026 |
| Mar 1, 2026 | Jian Xie President and COO | FTax withholding Common Stock | -8,147 | $15.33 | $125k | 375,313 | Mar 2, 2026 |
| Feb 23, 2026 | Jian Xie President and COO | FTax withholding Common Stock | -655 | $23.01 | $15k | 331,383 | Feb 25, 2026 |
| Feb 23, 2026 | Paul Kim CFO and Treasurer | FTax withholding Common Stock | -661 | $23.01 | $15k | 327,485 | Feb 25, 2026 |
| Feb 23, 2026 | Hanlin Gao Chief Scientific Officer | FTax withholding Common Stock | -403 | $23.01 | $9,273 | 951,156 | Feb 25, 2026 |
| Feb 23, 2026 | Ming Hsieh Chief Executive Officer | FTax withholding Common Stock | -2,167 | $23.01 | $50k | 797,054 | Feb 25, 2026 |
| Feb 24, 2026 | Ming Hsieh Chief Executive Officer | AGrant or award Common Stock | +19,067 | $0.00 | $0 | 816,121 | Feb 25, 2026 |
| Feb 24, 2026 | Hanlin Gao Chief Scientific Officer | AGrant or award Common Stock | +4,891 | $0.00 | $0 | 956,047 | Feb 25, 2026 |
| Feb 24, 2026 | Paul Kim CFO and Treasurer | AGrant or award Common Stock | +5,721 | $0.00 | $0 | 333,206 | Feb 25, 2026 |
| Feb 24, 2026 | Jian Xie President and COO | AGrant or award Common Stock | +5,862 | $0.00 | $0 | 337,245 | Feb 25, 2026 |
| Feb 24, 2026 | Ming Hsieh Chief Executive Officer | AGrant or award Common Stock | +39,802 | $0.00 | $0 | 855,923 | Feb 25, 2026 |
| Feb 24, 2026 | Paul Kim CFO and Treasurer | AGrant or award Common Stock | +14,926 | $0.00 | $0 | 348,132 | Feb 25, 2026 |
| Feb 24, 2026 | Jian Xie President and COO | AGrant or award Common Stock | +15,299 | $0.00 | $0 | 352,544 | Feb 25, 2026 |
| Feb 24, 2026 | Hanlin Gao Chief Scientific Officer | AGrant or award Common Stock | +12,762 | $0.00 | $0 | 968,809 | Feb 25, 2026 |
| Feb 24, 2026 | Ming Hsieh Chief Executive Officer | AGrant or award Common Stock | +59,276 | $0.00 | $0 | 915,199 | Feb 25, 2026 |
| Feb 24, 2026 | Hanlin Gao Chief Scientific Officer | AGrant or award Common Stock | +22,806 | $0.00 | $0 | 991,615 | Feb 25, 2026 |
| Feb 24, 2026 | Paul Kim CFO and Treasurer | AGrant or award Common Stock | +26,673 | $0.00 | $0 | 374,805 | Feb 25, 2026 |
| Feb 24, 2026 | Jian Xie President and COO | AGrant or award Common Stock | +27,341 | $0.00 | $0 | 379,885 | Feb 25, 2026 |
| Feb 24, 2026 | Ming Hsieh Chief Executive Officer | FTax withholding Common Stock | -10,230 | $23.09 | $236k | 904,969 | Feb 25, 2026 |
| Feb 24, 2026 | Hanlin Gao Chief Scientific Officer | FTax withholding Common Stock | -2,489 | $23.09 | $57k | 989,126 | Feb 25, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Linda Dongdirector
- Regina E Grovesdirector
- Hanlin GaoChief Scientific Officer
- Ming HsiehChief Executive Officer
- Paul KimCFO and Treasurer
- Michael Nohailedirector
- Jian XiePresident and COO
Questions about FLGT
Answered from the filings on this page, as of the latest one.
Are insiders buying FLGT?
As of Sep 3, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 2 open-market sells worth $75k by 2 insiders at Fulgent Genetics, Inc. in the last 90 days, net -$75k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade FLGT on the open market?
Hanlin Gao (Chief Scientific Officer) sold $33k of FLGT on Sep 2, 2026 and filed the Form 4 on Sep 3, 2026. InsiderTell scored 29 (weak), with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at Fulgent Genetics, Inc.?
7 people have filed a Form 4 at Fulgent Genetics, Inc., among them Linda Dong (director), Regina E Groves (director), Hanlin Gao (Chief Scientific Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.